Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novel Biotechnology
Toronto, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Novel Biotechnology has developed and launched its proprietary NBx platform enabling scalable, high-yield production of complex plasmid DNA for use in gene therapy, mRNA therapeutics, and synthetic biology, with commercial services launched as of Q4 2023, supporting rapid and high-quality DNA delivery to partners
- Modalities
- Plasmid DNARecombinant DNA
- Industry
- Contract Manufacturing Organization
02
Partnerships
Ontario Center of InnovationUnnamed external partners
Beyond the preview
Go deeper on Novel Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel Biotechnology.